Dutch gene therapy specialist uniQure (Nasdaq: QURE) has appointed Matthew Kapusta as chief financial officer.
He has 20 years of experience in life science, including investment banking, finance and corporate development. He will be based in the Massachusetts manufacturing facility.
Jörn Aldag, chief executive of uniQure, said: "As a former life sciences investment banker, Matthew has led many financial transactions and he has acquired a tremendous amount of experience as an executive in life science companies.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze